Archives
-
Mitochondrial IRF3 in Bleomycin Lung Fibrosis
2026-09-29
The reference study identifies mitochondrial translocation of activated IRF3 as a mechanistic link between cGAS-STING signaling, defective mitophagy, ferroptosis, and pulmonary fibrosis. Its combination of mouse, epithelial-cell, biochemical, imaging, and flux-based assays provides a useful framework for dissecting how inflammatory signaling becomes mitochondrial injury.
-
Astrocytic GAT-3 in Dentate Gyrus Memory
2026-09-29
This study shows that astrocytic GAT-3 is an active regulator of dentate gyrus synaptic transmission, linking GABA uptake to astrocytic Ca2+ signaling, presynaptic GluN2B-NMDAR activity, and contextual fear-memory formation. Its multimodal design provides a useful framework for studying neuron–astrocyte interactions while clarifying how pharmacological controls can distinguish transporter-mediated signaling from receptor-mediated GABA effects.
-
4-MUG for Lysosomal Enzyme Activity Assays
2026-09-28
4-MUG converts β-glucosidase and β-glucocerebrosidase activity into a sensitive fluorescent readout suited to lysosomal disease models, enzyme kinetics, and screening. This practical guide connects assay design with recent GBA1 mRNA research while emphasizing calibration, workflow controls, and troubleshooting.
-
Exo1 for Exocytosis Assays: Workflow & Insights
2026-09-28
Exo1 offers an acute way to probe Golgi-to-ER traffic and distinguish ARF1-linked effects from some actions of Brefeldin A. This practical guide shows how to build a controlled exocytosis assay—and how to connect trafficking readouts to tumor extracellular-vesicle research without overstating what Exo1 has been shown to do.
-
15-PGDH Inhibition Supports Muscle Repair During Weight Loss
2026-09-27
A 2026 PNAS mouse study reports that inhibiting 15-PGDH improves muscle stem-cell activity, regenerated muscle-fiber growth, and strength recovery during semaglutide-associated weight loss. The findings suggest a potential way to address muscle-repair deficits while retaining weight-loss effects, but they do not establish clinical benefit or a human treatment strategy.
-
MLN4924 and CRL5–APC/C Crosstalk in Cancer
2026-09-26
MLN4924 is a selective NEDD8-activating enzyme inhibitor for probing how neddylation shapes ubiquitin-ligase activity. This article connects its broad pathway effects to emerging CRL5–APC/C crosstalk and shows how that distinction can sharpen cancer biology experiments.
-
Coumestrol in Cell Assays: A Practical Design Guide
2026-09-25
This scenario-driven guide shows how to plan viability, proliferation, and cytotoxicity experiments with Coumestrol (SKU C5832), while distinguishing receptor pharmacology from the higher-concentration effects reported in rheumatoid arthritis fibroblast-like synoviocytes. It covers assay interpretation, solution handling, vendor selection, and evidence-based limits.
-
GABAB Antagonism in Astrocyte–Neuron Research
2026-09-25
A translational framework for using CGP 55845 hydrochloride to test GABAB-dependent contributions to synaptic signaling—while keeping astrocytic GAT-3 mechanisms and their evidential limits distinct.
-
EGTA and Calcium Causality in Neural Assays
2026-09-24
EGTA (egtazic acid) helps researchers test whether calcium availability is necessary for a cellular response—not which channel produced it. This article connects selective chelation to the interpretation of neural electrophysiology, injury models, and practical assay design.
-
Wortmannin: From PI3K Mechanism to Translation
2026-09-24
A mechanistic and translational guide to using Wortmannin to interrogate PI3K signaling, cancer biology, and viral entry—while accounting for its irreversible action, kinase cross-reactivity, and experimental limits.
-
DiI (DiIC18(3)) Membrane Probe Workflow
2026-09-23
DiI (DiIC18(3)) labels lipid membranes with orange-red fluorescence, supporting membrane visualization, neuronal tracing, and selected cell-based assays. It is insoluble in water, so use an appropriate organic solvent and do not treat it as an aqueous stain or a selective intracellular-organelle marker.
-
Eimeria Infection, Sulfachlorpyridazine, and Cecal Omics
2026-09-23
The reference study integrates 16S rRNA gene sequencing with LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment reshape the chicken cecal environment. Its results distinguish the microbiota-stabilizing pattern associated with ethanamizuril from the reduction of potentially harmful Escherichia-Shigella linked to sulfachlorpyridazine, while showing limited effects from their low-dose combination.
-
Drug Repurposing for DNA Repair in CRISPR
2026-09-22
This study presents a large-scale screen of approved drugs to identify compounds that shift CRISPR-induced double-strand break repair toward NHEJ, MMEJ, or HDR. Its findings connect repair-outcome engineering with synthetic lethality and provide a framework for validating pathway modulators in genome editing, disease modeling, and cancer research.
-
Erastin and Ferroptosis: Assay Logic Beyond Viability
2026-09-22
Erastin is a ferroptosis inducer best used as a mechanistic perturbation rather than a standalone viability reagent. This guide connects redox biology, RAS/BRAF genotype, and necroptosis-aware assay design to improve interpretation in ferroptosis research.
-
SETD7, White Adipose Browning, and Metabolic Health
2026-09-21
The reference study identifies SETD7 as a negative regulator of inguinal white adipose tissue thermogenesis and links its depletion to an Adcy7–Sirt1–Creb1 signaling axis. Its mouse and adipocyte experiments suggest that selectively enhancing beige-fat function, rather than simply increasing adipogenesis, may improve energy expenditure and resistance to diet-induced metabolic dysfunction.